Drug Guidance for Subsidy 06/02/2026 Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended zolbetuximab, in combin... See all × 06/02/2026 Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended zolbetuximab, in combination with chemotherapy, for inclusion on the MOH List of Subsidised Drugs for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma. The decision was based on the unfavourable cost effectiveness of zolbetuximab plus chemotherapy compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for zolbetuximab plus chemotherapy are provided in the Annex.
INTRAVENOUS Select a brand starting with the letter: V VYLOY™ POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL [SIN17197P]